Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%Business Wire • 06/29/23
K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)PRNewsWire • 06/28/23
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)Business Wire • 06/26/23
Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023Business Wire • 06/17/23
Bristol Myers Squibb sues federal government over Medicare drug negotiations: reportMarket Watch • 06/16/23
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) LabelBusiness Wire • 06/16/23
Goldman Sachs Says Traders Should Use Options to Load Up on These 5 ‘Strong Buy' Blue Chips24/7 Wall Street • 06/15/23
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/13/23
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, MassachusettsBusiness Wire • 06/08/23